CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 inhibitors such as nivolumab [2, 3], pembrolizumab [4], and atezolizumab [5], have revolutionized NSCLC treatment by significantly prolonging survival.